<sup>90</sup>Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors
Helena Lanzafame(Düsseldorf University Hospital), Rainer Hamacher(Technical University of Munich), Christoph E. Heilig(German Cancer Research Center), Pedro Fragoso Costa(Essen University Hospital), Sebastian Bauer(University of Duisburg-Essen), Martin Schüler(Essen University Hospital), Eva Wardelmann(University Hospital Münster), Simon Kreutzfeldt(German Cancer Research Center), Kim M. Pabst(Klinik und Poliklinik für Nuklearmedizin), Ilektra Antonia Mavroeidi(Essen University Hospital), Wolfgang P. Fendler(Essen University Hospital), Mélanie Desaulniers(Université de Sherbrooke), Sebastian Mühl(University of Münster), Jens T. Siveke(German Cancer Research Center), Michael Nader(Deutsches Konsortium für Translationale Krebsforschung), Ina Pretzell(Essen University Hospital), Stephan Leyser(Düsseldorf University Hospital), Stefan Fröhling(German Cancer Research Center), Leila Kamkar(German Cancer Research Center), Ken Herrmann(Klinikum rechts der Isar)
Cited by 10
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k